Compare · ARGX vs LXEO
ARGX vs LXEO
Side-by-side comparison of argenx SE (ARGX) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 165.7x LXEO ($330.6M).
- Over the past year, ARGX is up 51.2% and LXEO is down 3.4% - ARGX leads by 54.7 points.
- ARGX has been more active in the news (5 items in the past 4 weeks vs 3 for LXEO).
- ARGX has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- argenx SE
- Lexeo Therapeutics Inc.
- Price
- $882.63-1.03%
- $4.23-2.98%
- Market cap
- $54.76B
- $330.6M
- 1M return
- +12.11%
- -27.19%
- 1Y return
- +51.24%
- -3.42%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2023
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest LXEO
- Chief Operating Officer Otero Jose Manuel sold $6,606 worth of shares (1,302 units at $5.07), decreasing direct ownership by 0.99% to 130,088 units (SEC Form 4) (for withholding tax)
- Chief Executive Officer Townsend Richard Nolan sold $16,927 worth of shares (3,342 units at $5.06), decreasing direct ownership by 0.98% to 336,764 units (SEC Form 4) (for withholding tax)
- Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- SEC Form 10-Q filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
- SEC Form 4 filed by Director Sepp-Lorenzino Laura
- SEC Form 3 filed by new insider Sepp-Lorenzino Laura
- SEC Form DEFA14A filed by Lexeo Therapeutics Inc.